GHRP-2, GHRP-6, and ipamorelin are all GHSR-1a agonists that stimulate pituitary GH release — but they differ substantially in receptor selectivity, cortisol and prolactin co-stimulation, appetite effects, and what research questions they are best suited to answer. Choosing the wrong compound introduces confounds that can invalidate a study design.
Shared Mechanism: GHSR-1a Activation
All three compounds activate GHSR-1a — the receptor for ghrelin, the endogenous ‘hunger hormone’ produced primarily by the stomach. GHSR-1a is a Gq-coupled GPCR expressed on pituitary somatotrophs (where activation stimulates GH release via IP3/PKC/Ca2+ signalling), the hypothalamus (appetite and energy balance), and GI tract. GHRP-2, GHRP-6, and ipamorelin were all designed to activate this receptor and stimulate GH release — the distinction between them is their selectivity and off-target activity at other receptors and pathways.
GHRP-2: The Balanced GHSR-1a Agonist
GHRP-2 (growth hormone-releasing peptide 2) is a synthetic hexapeptide (D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH2) that activates GHSR-1a with high potency. It produces robust GH release and moderate co-stimulation of cortisol and prolactin secretion — more selective than GHRP-6 but less selective than ipamorelin.
Cortisol co-stimulation: GHRP-2 stimulates ACTH-independent cortisol release from the adrenal cortex via a mechanism involving direct adrenal GHSR-1a or a related receptor. This cortisol co-stimulation is moderate and generally not problematic for short-term GH axis studies, but it introduces HPA axis activation as a confound in studies where glucocorticoid-sensitive endpoints are being measured.
Research use: When moderate cortisol co-stimulation is acceptable and GH pulse amplitude vs ipamorelin is the priority. Also appropriate when the research question involves GHSR-1a biology more broadly, not just GH release in isolation.
GHRP-6: The Ghrelin Mimetic
GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) with the most ghrelin-like activity profile of the three. It activates GHSR-1a robustly but also produces stronger appetite stimulation, higher cortisol and prolactin co-stimulation, and more GI motility effects than GHRP-2 or ipamorelin.
Appetite stimulation: GHRP-6 strongly activates GHSR-1a in the hypothalamic arcuate nucleus, stimulating NPY/AgRP orexigenic neurons and producing measurable increases in food intake in rodent models. This is the most pronounced appetite effect of the three compounds — making GHRP-6 the appropriate tool when ghrelin-like appetite effects are part of the research model, and a confound when they are not.
GI motility: GHSR-1a activation in the GI tract by GHRP-6 stimulates GI motility (prokinetic effect) — a distinct pharmacological action with applications in GI research but a potential confound in metabolic studies where GI absorption rates affect the measurement.
Research use: When the research question involves the full ghrelin biological profile — appetite stimulation, GI motility, GH release, and HPA activation together. Also in studies specifically examining the ghrelin axis in energy homeostasis where appetite stimulation is the desired effect, not a confound.
Ipamorelin: The Selective GHSR-1a Agonist
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) developed specifically for selectivity at GHSR-1a. It was designed to maximise GH stimulation while eliminating the cortisol, prolactin, and appetite side effects that characterise GHRP-2 and GHRP-6. It is currently the most selective GHSR-1a agonist available as a research tool.
Minimal cortisol co-stimulation: In multiple studies, ipamorelin has demonstrated no significant ACTH or cortisol increase at doses producing robust GH release. This selectivity makes ipamorelin the appropriate choice when HPA axis activation is a concern — studies measuring glucocorticoid-sensitive gene expression, immune function, bone metabolism, or any endpoint where cortisol elevation confounds the measurement.
Minimal prolactin co-stimulation: Unlike GHRP-2 and GHRP-6, ipamorelin does not meaningfully elevate prolactin. For studies involving lactation, reproductive biology, or any prolactin-sensitive endpoint, ipamorelin is the appropriate GH secretagogue.
Minimal appetite effect: Ipamorelin’s selectivity profile includes minimal hypothalamic NPY/AgRP activation, producing little to no appetite stimulation at effective GH-releasing doses. This eliminates a major confound in metabolic studies where food intake is a measured endpoint.
Research use: The default choice for isolated GH axis stimulation studies where HPA confounds must be minimised. The standard partner for CJC-1295 No DAC in combined GHRH-R + GHSR-1a protocols.
Side-by-Side Comparison
| Property | GHRP-2 | GHRP-6 | Ipamorelin |
|---|---|---|---|
| Receptor target | GHSR-1a (primary) | GHSR-1a (primary) | GHSR-1a (highly selective) |
| GH release potency | High | High | High (lower peak than GHRP-2 in some models) |
| Cortisol co-stimulation | Moderate ↑ | High ↑ | Minimal / none |
| Prolactin co-stimulation | Moderate ↑ | Moderate–High ↑ | Minimal / none |
| Appetite stimulation | Mild | Strong (ghrelin-like) | Minimal |
| GI motility effects | Mild | Moderate (prokinetic) | Minimal |
| Half-life | ~1–2 hours | ~1–2 hours | ~2 hours |
| Best for | Moderate HPA acceptable; broader GHSR-1a profile | Full ghrelin axis simulation; appetite research | Isolated GH stimulation; HPA-sensitive endpoints |
| Typical combination | + CJC-1295 No DAC | + CJC-1295 No DAC (if appetite confound acceptable) | + CJC-1295 No DAC (standard combination) |
Combined Protocols: CJC-1295 + GHSR-1a Agonist
The most common GH secretagogue research protocol combines a GHRH-R agonist (CJC-1295 No DAC or sermorelin) with a GHSR-1a agonist (ipamorelin most commonly) to stimulate both independent GH-releasing pathways simultaneously. The rationale:
- GHRH-R activation (CJC-1295) increases cAMP in somatotrophs, enhancing GH synthesis and secretion via PKA
- GHSR-1a activation (ipamorelin) triggers Ca2+-dependent GH vesicle exocytosis via IP3/PKC and additionally suppresses somatostatin tone
- The combined signal is synergistically greater than either pathway alone — because GHRH-R and GHSR-1a converge on different steps of secretion, and somatostatin suppression by GHSR-1a disinhibits the pituitary’s response to GHRH
- CJC-1295 + ipamorelin most closely replicates the physiological dual trigger for endogenous GH pulses: simultaneous GHRH release and somatostatin withdrawal
When to use GHRP-6 vs ipamorelin in combined protocols
If appetite stimulation and GI prokinetic effects are study endpoints or desirable outcomes, use GHRP-6. If they are confounds, use ipamorelin. For the vast majority of GH axis mechanistic studies, ipamorelin is the appropriate choice because it allows attribution of experimental effects to GH axis activation without HPA, appetite, or GI confounds.
Frequently Asked Questions
What is the difference between GHRP-2, GHRP-6, and ipamorelin?
All three are GHSR-1a (growth hormone secretagogue receptor) agonists that stimulate pituitary GH release. The key differences are selectivity and co-stimulation. Ipamorelin is the most selective — it stimulates GH release with minimal cortisol or prolactin co-stimulation, making it the cleanest research tool for isolated GH axis studies. GHRP-2 produces moderate cortisol and prolactin co-stimulation in addition to GH release. GHRP-6 produces the highest cortisol, prolactin, and ghrelin effects and strongly stimulates appetite — it most closely mimics endogenous ghrelin’s full biological profile.
Which is stronger — GHRP-2 or GHRP-6?
Both GHRP-2 and GHRP-6 produce robust GH release via GHSR-1a activation and are broadly comparable in GH stimulation potency in most research models. GHRP-2 is generally considered the more GH-selective of the two with somewhat less appetite stimulation than GHRP-6. GHRP-6 produces stronger ghrelin-like effects including greater appetite stimulation and higher cortisol co-stimulation. For maximum GH release with fewer GI side effects, GHRP-2 is typically preferred.
What is GHSR-1a?
GHSR-1a (growth hormone secretagogue receptor type 1a) is the receptor for ghrelin — the endogenous ‘hunger hormone’ produced primarily by the stomach. GHSR-1a is expressed on pituitary somatotrophs (where it stimulates GH release), the hypothalamus (appetite regulation), and GI tract. GHRP-2, GHRP-6, and ipamorelin are all synthetic GHSR-1a agonists designed to activate this receptor. Ipamorelin was specifically engineered for selectivity at GHSR-1a over other receptors; GHRP-2 and GHRP-6 have broader receptor interaction profiles.
Why does GHRP-6 stimulate appetite?
GHRP-6 strongly activates GHSR-1a in the hypothalamus, particularly neurons in the arcuate nucleus that regulate appetite and energy balance. GHSR-1a activation in the hypothalamus stimulates NPY and AgRP orexigenic neurons while inhibiting POMC/CART neurons — shifting the hypothalamic balance toward hunger and increased food intake. This is the same appetite-stimulating mechanism as endogenous ghrelin, which GHRP-6 structurally mimics more closely than ipamorelin or GHRP-2.
Can GHRP-2 and ipamorelin be combined with CJC-1295?
Yes. Combining a GHSR-1a agonist (GHRP-2, GHRP-6, or ipamorelin) with a GHRH-R agonist (CJC-1295 No DAC or sermorelin) produces synergistically greater GH pulse amplitude than either alone. The most common research combination is CJC-1295 No DAC + ipamorelin — because ipamorelin’s selectivity minimises HPA confounds while the combined GHRH-R + GHSR-1a stimulation maximises GH pulse amplitude. This combination most closely replicates the physiological dual trigger for endogenous GH pulses.
GHRP-2 · GHRP-6 · Ipamorelin · CJC-1295 No DAC · Sermorelin